HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Thromboplastin (Tissue Factor)

Subscribe to New Research on Thromboplastin

Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.

Also Known As:

Tissue Factor; Blood Coagulation Factor III; Coagulin; Glomerular Procoagulant Activity; Prothrombinase; Tissue Factor Procoagulant; Urothromboplastin; Activity, Glomerular Procoagulant; Factor III, Coagulation; Procoagulant Activity, Glomerular; Procoagulant, Tissue Factor; Thromboplastin, Tissue; Antigens, CD142; CD142 Antigens; Coagulation Factor III; Factor III; Tissue Thromboplastin; Blood-coagulation factor III

Networked: 2949 relevant articles (37 outcomes, 249 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mackman, Nigel: 38 articles (12/2012 - 07/2002)
2.	Ruf, Wolfram: 20 articles (10/2012 - 04/2003)
3.	Levi, Marcel: 12 articles (07/2012 - 02/2002)
4.	Rak, Janusz: 10 articles (12/2012 - 02/2004)
5.	Furie, Bruce: 9 articles (09/2012 - 10/2002)
6.	Tanner, Felix C: 9 articles (05/2012 - 02/2006)
7.	Lüscher, Thomas F: 9 articles (05/2012 - 04/2002)
8.	Spek, C Arnold: 9 articles (09/2011 - 11/2003)
9.	Kisiel, Walter: 9 articles (02/2009 - 06/2003)
10.	Jilma, Bernd: 9 articles (04/2008 - 05/2002)

Related Diseases

1.	Disseminated Intravascular Coagulation 06/01/2011 - "Tissue factor as a target for the treatment of disseminated intravascular coagulation." 04/01/2008 - "Additionally, one should exercise caution if there is evidence of activated coagulation, such as that seen with excessive tissue factor release or disseminated intravascular coagulation. " 01/01/2002 - "Because pathophysiology differed remarkably between the tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats, we recommend that they be assessed carefully as distinct entities to determine implications of their experimental and clinical use." 01/01/2002 - "Tissue factor and lipopolysaccharide frequently have been used to induce disseminated intravascular coagulation in experimental animal models. " 01/01/2002 - "Marked difference in pathophysiology between tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats." Order ALL the reference details at left...
2.	Thrombosis (Thrombus) 01/01/2010 - "The aim of the current study was to investigate whether differences exist among strains in models of hemostasis and thrombosis and whether these differences are reflected in differences in the tissue factor (TF) pathway. " 03/01/1996 - "The aim of this study was to compare recombinant thromboplastin (rTF, ISI = 0.82) with rabbit thromboplastin (RT, ISI = 1.46) in order to evaluate which performed better in our thrombosis centre. " 01/01/1987 - "(1) Study on the role of tissue thromboplastin in the formation of thrombosis]." 09/06/2012 - "Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation." 09/01/2012 - "Tissue factor (TF), the primary initiator of coagulation in vivo, plays a major role in both thrombosis and hemostasis. " Order ALL the reference details at left...
3.	Neoplasms (Cancer) 11/15/2009 - "In cancer patients without VTE, a retrospective analysis revealed a 1-year cumulative incidence of VTE of 34.8% in patients with tissue factor-bearing microparticles versus 0% in those without detectable tissue factor-bearing microparticles (Gray test P = 0.002).The median number of tissue factor-bearing microparticles in the cancer VTE cohort (7.1 x 10(4) microparticles/microL) was significantly greater than both the idiopathic VTE and cancer-no VTE groups (P = 0.002 and P = 0.03, respectively). " 06/07/2012 - "In the present study, we analyzed tissue factor (TF) expression in 4 different human pancreatic tumor cell lines for the purpose of producing derivative tumors in vivo. " 02/01/2011 - "This study determines the impact of tissue factor (TF)-signaling on the extrinsic pathway of apoptosis in cancer cells and propose death associated protein kinase-1 (DAPK1) as a novel key regulator. " 06/01/2010 - "In this study, we analyzed levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE. " 10/01/2009 - "More studies are needed to clarify the mechanisms by which tissue factor affects cancer progression and outcome, and its potential role as a therapeutic target." Order ALL the reference details at left...
4.	Hemorrhage 04/01/2010 - "In preliminary studies on low tissue factor mice, there also appears to be a delay in wound healing with evidence of bleeding into the granulation tissue. " 01/01/2009 - "This study was undertaken to evaluate prospectively how tissue factor (TF) activated TEG correlated to clinical signs of bleeding in dogs, compared to a routine coagulation profile. " 04/01/2008 - "A patient with spontaneous hemorrhage from multiple body sites was found to have markedly prolonged international normalized ratio (INR) and activated partial thromboplastin times (aPTT) with incomplete correction of aPTT on mixing studies using normal plasma. " 01/01/2005 - "This study investigates the predictive value of commonly used coagulation tests (thromboplastin time, partial thromboplastin time and thrombocyte count) compared with a standardized bleeding history. " 07/01/1981 - "The Australasian Reference Thromboplastin: I. A study in bleeding patients." Order ALL the reference details at left...
5.	Myocardial Infarction 02/01/2009 - "This study was aimed to investigate the change of tissue factor pathway (TFP) ratio during the attack of acute myocardial infarction (AMI) and its clinical significance. " 09/01/2012 - "Lower tissue factor inhibition in patients with ST segment elevation than in patients with non ST elevation acute myocardial infarction." 06/01/2011 - "[Expression of tissue factor in monocytes and plasma during acute phase and recovery stage of patients with myocardial infarction]." 06/01/2009 - "Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation." 02/01/2009 - "[Change of tissue factor pathway ratio during attack in patients with acute myocardial infarction and its clinical significance]." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Factor Xa (Coagulation Factor Xa)
2.	Heparin (Liquaemin)
3.	Thrombin
4.	Prothrombin (Factor II)
5.	Anticoagulants
6.	Dacarbazine (DIC)
7.	Fibrinogen (Factor I)
8.	Plasminogen Activators (Plasminogen Activator)
9.	Thrombomodulin
10.	Antithrombin III

Related Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy)
2.	Immunomodulation
3.	Transplants (Transplant)
4.	Organ Transplantation
5.	Drug Therapy (Chemotherapy)

blog comments powered by Disqus

TREATMENT OPTIONS
for Disseminated Intravascular Coagulation,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 110 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>